Conservative care in Europe—nephrologists’ experience with the decision not to start renal replacement therapy
Moniek W.M. van de Luijtgaarden(Amsterdam UMC Location University of Amsterdam), Kitty J. Jager(Amsterdam University Medical Centers), Patrik Finne(Hospital District of Helsinki and Uusimaa), Willem Jan W. Bos(St. Antonius Ziekenhuis), José Luis Górriz(Universitat de València), Wim Van Biesen(Ghent University Hospital), Vianda S Stel(Amsterdam UMC Location University of Amsterdam), Giovanni Cancarini(Brescia University), Cécile Couchoud(Agence de la Biomédecine), Marlies Noordzij(University of Amsterdam), Friedo W. Dekker(Leiden University Medical Center), Charles Tomson(Freeman Hospital), Olivera Stojceva-Taneva(PHI University Psychiatric Clinic - Skopje), Svjetlana Čala(University of Zagreb), Christos Iatrou(General Hospital of Nikea), Christoph Wanner(Universitätsklinikum Würzburg)
Cited by 64
Related Papers
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Clinical practice guideline on diagnosis and treatment of hyponatraemia
|Intensive Care Medicine|2014|1k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|969
A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
|Kidney International|2019|886